Cargando…

Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double‐blind placebo‐controlled cross‐over study

Measuring muscle velocity recovery cycles (MVRCs) is a method to obtain information on muscle cell excitability, independent of neuromuscular transmission. The goal was to validate MVRC as a pharmacodynamic (PD) biomarker for drugs targeting muscle excitability. As proof‐of‐concept, sensitivity of M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruijs, Titia Q., Koopmans, Ingrid W., de Kam, Marieke L., Tannemaat, Martijn R., Groeneveld, Geert Jan, Heuberger, Jules A. A. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747120/ https://www.ncbi.nlm.nih.gov/pubmed/36281627 http://dx.doi.org/10.1111/cts.13418

Ejemplares similares

Effects of Mexiletine and Lacosamide on Nerve Excitability in Healthy Subjects: A Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study
por: Ruijs, Titia Q., et al.
Publicado: (2022)

Transcranial magnetic stimulation as biomarker of excitability in drug development: A randomized, double‐blind, placebo‐controlled, cross‐over study
por: Ruijs, Titia Q., et al.
Publicado: (2022)

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective Na(V)1.8 Inhibitor, in Healthy Male Adults
por: Hijma, Hemme J, et al.
Publicado: (2021)

A patient with mexiletine-related psychosis
por: Shailesh, Fnu, et al.
Publicado: (2011)

Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy Subjects
por: van Esdonk, Michiel J., et al.
Publicado: (2018)

Experience with oral mexiletine in primary erythromelalgia in children
por: Iqbal, Javeed, et al.
Publicado: (2009)

Molecular Modeling of Cardiac Sodium Channel with Mexiletine
por: Zhorov, Boris S.
Publicado: (2022)

Fit for purpose of on-the-road driving and simulated driving: A randomised crossover study using the effect of sleep deprivation
por: Koopmans, Ingrid, et al.
Publicado: (2023)

Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation
por: Liu, Guizhi, et al.
Publicado: (2017)

A phase I, randomized, double‐blind, placebo‐controlled, single‐ and multiple dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VX‐128, a highly selective Na(v)1.8 inhibitor, in healthy adults
por: Hijma, Hemme J., et al.
Publicado: (2021)

Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders
por: Vissers, Maurits F. J. M., et al.
Publicado: (2021)

Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients
por: Moss, Laurence M., et al.
Publicado: (2022)

Study protocol for the MEXiletine hydrochloride administration trial: a placebo-controlled, randomised, double-blind, multicentre, crossover study of its efficacy and safety in spinal and bulbar muscular atrophy (MEXPRESS)
por: Yamada, Shinichiro, et al.
Publicado: (2018)

Effectiveness and safety of mexiletine in patients at risk for (recurrent) ventricular arrhythmias: a systematic review
por: van der Ree, Martijn H, et al.
Publicado: (2022)

Management of ventricular tachycardia--role of mexiletine : proceedings of a symposium held in Copenhagen, Denmark, 25th-27th May, 1978 /
Publicado: (1978)

A Case of Mexiletine-induced Hypersensitivity Syndrome Presenting as Eosinophilic Pneumonia
por: Lee, Sang-Pyo, et al.
Publicado: (2010)

Therapeutic drug monitoring of mexiletine at a large academic medical center
por: Nei, Scott D, et al.
Publicado: (2016)

Case report: Mexiletine suppresses ventricular arrhythmias in Andersen-Tawil syndrome
por: Yang, Jing, et al.
Publicado: (2022)

Mexiletine in spinal and bulbar muscular atrophy: a randomized controlled trial
por: Yamada, Shinichiro, et al.
Publicado: (2022)

Tolerance to Opioid‐Induced Respiratory Depression in Chronic High‐Dose Opioid Users: A Model‐Based Comparison With Opioid‐Naïve Individuals
por: Algera, Marijke Hyke, et al.
Publicado: (2020)

Mexiletine Differentially Restores the Trafficking Defects Caused by Two Brugada Syndrome Mutations
por: Moreau, Adrien, et al.
Publicado: (2012)

Mexiletine Treatment for Neonatal LQT3 Syndrome: Case Report and Literature Review
por: Bagkaki, Alena, et al.
Publicado: (2021)

Mexiletine and False Positive Urine Drug Screen for Amphetamine: A Case Review
por: Sohal, Sumit, et al.
Publicado: (2021)

Mexiletine-like cellular electrophysiological effects of GS967 in canine ventricular myocardium
por: Hézső, Tamás, et al.
Publicado: (2021)

Designer Gelators for the Crystallization of a Salt Active Pharmaceutical Ingredient—Mexiletine Hydrochloride
por: Andrews, Jessica L., et al.
Publicado: (2022)

Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers
por: Peters, Esther, et al.
Publicado: (2016)

Interactions of Mexiletine with Novel Antiepileptic Drugs in the Maximal Electroshock Test in Mice: An Isobolographic Analysis
por: Wróblewska, Dorota, et al.
Publicado: (2018)

Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment
por: Kim, Hyun-Ji, et al.
Publicado: (2019)

Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo‐Controlled, Phase II Trial
por: Niemeyer‐van der Kolk, Tessa, et al.
Publicado: (2020)

Biperiden Challenge Model in Healthy Elderly as Proof‐of‐Pharmacology Tool: A Randomized, Placebo‐Controlled Trial
por: Bakker, Charlotte, et al.
Publicado: (2021)

Anti-Bronchospasmodic Effect of JME-173, a Novel Mexiletine Analog Endowed With Highly Attenuated Anesthetic Activity
por: Carvalho, Katharinne Ingrid Moraes, et al.
Publicado: (2020)

An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists
por: Chen, Xia, et al.
Publicado: (2012)

Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
por: Prins, Samantha, et al.
Publicado: (2022)

Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m-hydroxymexiletine
por: Gualdani, Roberta, et al.
Publicado: (2015)

Mexiletine infusion challenge test for neonatal long QT syndrome with 2:1 atrioventricular block
por: Okuwaki, Hajime, et al.
Publicado: (2019)

Mexiletine shortens the QT interval in a pedigree of KCNH2 related long QT syndrome
por: Fujisawa, Taishi, et al.
Publicado: (2020)

Safety, pharmacokinetics, and pharmacodynamics of Gln‐1062, a prodrug of galantamine
por: Bakker, Charlotte, et al.
Publicado: (2020)

Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3
por: Mazzanti, Andrea, et al.
Publicado: (2016)

The Effect of Sodium Channel Blocker, Mexiletine, on Body Weight in Type 2 Diabetes Patients with Visceral Obesity
por: Ueno, Naohiko
Publicado: (2019)

Long-Term Safety and Usefulness of Mexiletine in a Large Cohort of Patients Affected by Non-dystrophic Myotonias
por: Modoni, Anna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c77hbqlvagb4fb67s025e8nfb8